Observe Medical ASA (OBSRV) Earnings Call Transcript & Summary
November 3, 2022
Earnings Call Speaker Segments
Rune Nystad
executiveGood morning, everyone, and welcome to Observe Medical's third quarter presentation. I'm Rune Nystad, the company's CEO. Joining me today is Per Arne Nygård, our CFO, who will take part in this presentation. This quarter has truly been a busy one — a period that has delivered progress along with some genuinely great opportunities, which we'll discuss today. From here on, the presentation will be conducted in English. If you take a look at Observe Medical's portfolio — which also forms today's agenda — we have the Biim device, an ultrasound device. We have a Nordic portfolio made up of various products sold mainly in Sweden. And then we have Sippi. Today, we are adding the UnoMeter portfolio, subject to the presentation. As highlighted in the presentation, there is a strong and natural link between Sippi and the UnoMeter portfolio. Looking at Observe Medical as a company, our long-term goal remains to reach NOK 1 billion in revenue and beyond. That is our objective, and it is what we strive for every single day. I mentioned UnoMeter — that is one step toward it, together with the rest of the portfolio Observe Medical holds today, yes.
Rune Nystad
executiveWe've been concentrating — and still are — on health economics, patient welfare, and data accuracy, and we see that within our own portfolio too. So what's going to get us there? This has come up before as well: we're eyeing substantial growth possibilities. Biim, Sippi, and the UnoMeter are cases in point. We're seeking synergy possibilities and faster rollout. The UnoMeter illustrates that. It's a broad portfolio with worldwide reach and clinically proven benefits — very important. We're also working to secure a robust management team. There's an example of that as well: our latest hire for technical chief, Carsten, who joined us from Fresenius — he represents the kind of resources, talent, and skills we must bring into the organization to deliver what we've committed to doing. Looking back to Q3, Sippi — we said earlier that we had to move the device's manufacturing site because a factory closed at an OEM partner of ours that operated in Belarus, so we've found a new manufacturing partner. We've made arrangements for production.
Rune Nystad
executiveVerification testing is underway — those are the final steps before we formally begin production of Sippi at this new site. Our collaboration with distributors continues. We're seeing more requests for the Sippi device, and that's not just in Europe — South America and Asia are asking too. We've done work to get the organization ready. Right now we're a fairly small team, but we need to be strong and bring in resources as we plan for Sippi's execution. MDR is a term many of you are familiar with. It's also a readiness effort for some of our resources, and we made progress on that during the last quarter. Let's spend a few minutes on Biim. We are giving Fresenius strong support with the training. The project is proceeding according to plan. There are specific steps they must take to go all -- or into all clinics in the U.S. that need to be in place before they take that big step. So I see a company that's dedicated and willing to implement ultrasound into every clinic in the U.S. And I've kept up my weekly dialogue with the executive team, members of the executive team, at Fresenius in order to keep the project on track.
Rune Nystad
executiveWe've produced things such as educational videos. Those are training videos we've rolled out and incorporated into the — into Fresenius' internal training system, so I feel optimistic that we'll keep — be seeing progress with Fresenius and — yes. If we turn to Nordic sales and the distribution platform. What's needed there is to — really to pursue tenders, which we keep doing. And we're attempting to bring products into the portfolio. We do have a product range, but both of us are working to bring products into the portfolio. UnoMeter and the Convatec deal represent a tremendous opportunity for that sales organization, where we can expand our business not only in Sweden but also across the Nordic region, in Norway, Denmark and Finland. And we carry on, as I said, with the organizational work. We've brought in Carsten Bøgh, who has global experience with Fresenius across Europe, Asia and U.S. And he's already well along in doing what he was hired to do. On the financial side. Our revenues came to NOK 3.4 million with a good gross margin of 41%. EBITDA stands at minus NOK 10.7 million, as we keep investing in all areas. Our cash is just under NOK 25 million. Looking at the equity situation, our equity is NOK 160.8 million, with an equity ratio of 70.8%.
Rune Nystad
executiveLet's spend a bit more time on the UnoMeter. This is a big deal. It's really exciting for a company like Observe. It fits with the strategy. It also shows that when you collaborate closely with a larger corporation, this is the kind of thing you can sometimes accomplish in life. It's a market-leading portfolio in the segment. Annual revenue comes to roughly EUR 18 million from sales in Europe plus certain countries in South America and Australia. The asking price is USD 4.2 million, with genuinely healthy margins. So why the link between, yes, Sippi and UnoMeter? Well, at each bedside where a UnoMeter is present, there's a spot for Sippi, which is why this interests us so much. And beyond that, as we mentioned in the CEO letter: the products and the brand names are shown here on the display on the screen. And that brings us to over 600 distributors. Convatec will make introductions and help open up those channels for Observe too. The products are sold in over 50 countries. These are patented. We're taking over ownership of the patents as well. And these are also well-established brand names in the industry.
Rune Nystad
executiveSo, what happened? Let me give you a bit of background on how we’re connected to Convatec. In May, when they announced that they were shutting their factory in Belarus, we got in touch with them to express our interest in the portfolio. We spent quite a lot of time working with them over the summer. Ultimately, in competition with other parties, they concluded that Observe Medical was the best-suited company for this. They operate in the same space, but we don’t compete with Convatec elsewhere in the rest of their business. So that’s the short version of what led to the agreement we now have with Convatec. Brand names such as the UnoMeter 500, the UnoMeter Safeti Plus and the UnoMeter Abdo-Pressure are well-known products and brands used by nurses around the world. That really says a lot about what a fantastic opportunity this is for the company. The deal rationale: it’s fast track. This is a big leap on the revenue side for Observe Medical. It has a strong market position, quite unique, in several countries. We’re talking about a 90% position in the space.
Rune Nystad
executiveAdding a product to your own portfolio in this manner carries low risk. There's no R&D involved. No research is required. You don't face the risk of failing while building this product. It's already proven. It holds regulatory approval, et cetera, et cetera, so my team and I simply need to set up production, push the products into the same channels as Convatec, and see how far we can take the UnoMeter portfolio. And naturally, the network is enormous, since we're able to work with more than 600 distributors globally. So, looking ahead on that basis—I've now been with the company for a few months. I believe we're turning a corner with UnoMeter. This is an add-on to the story we've told so far and what the company has spent so far. So if you look at Sippi and Biim. We keep supporting Fresenius with this multi-clinic effort. There are more than 3,000 clinics in the U.S. alone. The plan is to introduce or sell the Biim ultrasound device as well, so we carry on the weekly effort with that. With Sippi, it's all about getting this ready for production after -- since we've identified a new manufacturing partner.
Rune Nystad
executiveSo, the UnoMeter process. It's a major undertaking for us, but it can be done. Because the factory has shut down, we need to establish production. On the regulatory side, everything is already in place. This device is market-approved and is even being sold today, so market clearance doesn't leave much for us to do. As for resources, we need to build an organization capable of supporting an effort of this kind. On the sales side, we have a substantial job ahead in following up with distributors, but we're being introduced to all of them. And locating them is an easy task. Company-wide, we need to expand our organization in order to do business in more than 50 countries through more than 600 distributors. That takes more resources than we currently have. So, looking ahead, and looking at the company we are, nothing has really changed. This is what we're here to do, and this is what we've said previously that we intend to do. So we believe this represents a significant opportunity to add to Observe Medical's existing business and a big step forward toward becoming a NOK 1 million (sic) NOK 1 billion company and beyond.
Rune Nystad
executiveThat brings my presentation to a close, and now I'll take your questions.
Per Nygård
executiveWe've received a few web submissions, largely finance-related, and you'll begin responding to them. I'll come in afterward. They concern what happens from the results going forward — specifically, when a positive EBIT result will show up, plus revenue guidance for next year. Rune, would you like to start?
Rune Nystad
executiveYeah. We’ve encountered that question previously as well. Thanks to the UnoMeter process across the summer, we’re now considerably nearer to being able to say something about it. There’s still additional work needed with the Board and internally before we can answer it fully, but as I mentioned today, this is an EUR 18 million opportunity with healthy profit margins. That’s going to help. So we’ll give a complete answer to that question at a later point.
Per Nygård
executiveYes, yes. I'm in favor of that. And as Rune said during his presentation, we do have our revenue ambition. The possibility now in front of us will speed that process up, but we'll need to return later with the precise guidance for next year and the result guidance, I believe, yes. And there's also a question regarding how the transaction will be financed. How is Observe Medical going to finance the transaction?
Rune Nystad
executiveRight. This is something we will keep working on with the Board to resolve. I should note that, with Convatec, we still have a final agreement to reach with them for the full acquisition. And part of that process involves deciding, together with them, how we pay for this opportunity, so that has yet to be concluded.
Per Nygård
executiveRight, right. And we’re in close dialogue with the Board of Directors as well as with major shareholders in Observe Medical, so once we have more detail about the financing, we’ll come back. And we will, yes, look at different solutions, yes. Yes, that’s the question we received from the web. I’m not sure whether we have any questions from the audience. No.
Rune Nystad
executiveOkay, there are no questions coming in from the audience, so thank you so much.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Observe Medical ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Observe Medical ASA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Observe Medical ASA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.